Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;110(5):1207-1210.
doi: 10.3324/haematol.2024.286842. Epub 2025 Jan 9.

Serum B-cell maturation antigen could be a simple and accurate biomarker to identify and prognosticate monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

Masanori Toho  1 , Daisuke Ikeda  2 , Shuichi Aikawa  3 , Chiho Misono  3 , Mitsuaki Oura  4 , Fuminari Fujii  1 , Hajime Sakuma  1 , Atsushi Uehara  1 , R Ikako Tabata  1 , Kentaro Narita  1 , Masami Takeuchi  1 , Tomohisa Watari  3 , Yoshihito Otsuka  3 , Kosei Matsue  5
Affiliations

Serum B-cell maturation antigen could be a simple and accurate biomarker to identify and prognosticate monoclonal gammopathy of undetermined significance and smoldering multiple myeloma

Masanori Toho et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The violin plot and box-and-whisker plot demonstrate the distribution of serum B-cell maturation antigen levels. (A) Serum B-cell maturation antigen (sBCMA) levels increased with disease progression, reaching their highest levels in patients with active multiple myeloma (MM). (B) Patients who progressed to active MM within 5-years exhibited higher sBCMA levels in smoldering multiple myeloma (SMM). (C) Patients with immunoparesis demonstrated higher sBCMA levels compared to those without. HC: healthy control; MGUS: monoclonal gammopathy of undetermined significance.
Figure 2.
Figure 2.
Progression of smoldering multiple myeloma to symptomatic multiple myeloma within a 5-year period according to the serum B-cell maturation antigen level and the 2/20/20 model. (A) Kaplan-Meier curve representing time to progression (TTP) to symptomatic multiple myeloma (MM) within 5 years for each classification based on a cutoff of 100 ng/mL of serum B-cell maturation antigen (sBCMA) levels in patients with smoldering MM (SMM). (B) Kaplan-Meier curve representing TTP to symptomatic multiple myeloma (MM) within 5 years for each classification based on the 2/20/20 model in SMM patients. (C) The Sankey diagram illustrates the SMM classification by the 2/20/20 model and how these changes when stratified by the sBCMA levels. Int: intermediate.
See this image and copyright information in PMC

References

    1. Lakshman A, Rajkumar SV, Buadi FK, et al. . Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. - PMC - PubMed
    1. Mateos MV., Kumar S., Dimopoulos M.A., et al. . International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. - PMC - PubMed
    1. Novak AJ, Darce JR, Arendt BK, et al. . Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103(2):689-694. - PubMed
    1. Laurent SA, Hoffmann FS, Kuhn PH, et al. . γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:7333. - PMC - PubMed
    1. Ghermezi M, Li M, Vardanyan S, et al. . Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785-795. - PMC - PubMed

LinkOut - more resources